For Q1 FY2026 (ended March 31, 2026), Alamar Biosciences reported revenue of $26.0 million, a 98.9% increase year-over-year. Net loss widened to $21.3 million from $7.7 million in the prior year, and diluted EPS was -$1.74, compared to -$0.68. Operating loss was $12.3 million, up 44.4% from $8.6 million. Cash and cash equivalents stood at $64.6 million, while stockholders' equity was negative $178.1 million.
•Revenue surged 98.9% YoY to $26.0 million.
•Net loss deepened to $21.3 million, with diluted EPS of -$1.74.
•Operating loss increased 44.4% to $12.3 million.
•Cash balance was $64.6 million; equity was negative $178.1 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Alamar Biosciences, Inc., a proteomics company develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics.
The company's offering is utilized in research areas including immunology, neurology, and oncology. The company serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates globally. The company was incorporated in 2018 and is based in Fremont, California.
Alamar Biosciences, Inc. is a proteomics company that develops a proteomic liquid biopsy platform and sells instruments, consumables, and services for the early detection of diseases. The company's core technology is NULISA, a proteomics platform that detects and quantifies protein biomarkers with ultra-high sensitivity. Its main product is the ARGO high throughput (HT) System, a fully automated precision proteomics platform that performs multiplexed analysis to support biomarker analysis across discovery, translational research, and diagnostics. The company's offerings are used in research areas including immunology, neurology, and oncology. Alamar serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs.
On which stock exchange is Alamar Biosciences (ALMR) listed and in what currency?
Alamar Biosciences, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ALMR. The company's stock trades in United States Dollars (USD), which is the official currency of the United States where the company is headquartered. As a US-based company listed on a major US exchange, its financial reporting and stock price are denominated in USD.
What sector and industry does Alamar Biosciences (ALMR) operate in?
Alamar Biosciences operates in the Healthcare sector, specifically within the Medical Devices industry. As a proteomics company, it develops advanced platforms and tools for protein biomarker analysis, which are used in medical research and diagnostics. The company's products, such as the ARGO HT System and NULISA technology, are classified as medical devices because they are instruments and consumables designed for laboratory analysis and diagnostic applications. This places Alamar at the intersection of biotechnology and medical device manufacturing, focusing on early disease detection and precision medicine.
Where is Alamar Biosciences headquartered and what markets does it serve?
Alamar Biosciences, Inc. is headquartered in Fremont, California, United States. The company operates globally, serving research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs around the world. Its products are utilized in various research areas including immunology, neurology, and oncology. By offering a proteomic liquid biopsy platform and automated systems like the ARGO HT System, Alamar supports biomarker analysis across the continuum from discovery to translational research and diagnostics, catering to a global customer base in the life sciences and healthcare sectors.
How does Alamar Biosciences (ALMR) generate revenue?
Alamar Biosciences generates revenue through the sale of instruments, consumables, and services related to its proteomic liquid biopsy platform. The company's primary product is the ARGO high throughput (HT) System, a fully automated precision proteomics platform that performs ultra-high sensitivity and multiplexed analysis. Customers purchase the instrument and subsequently buy consumables for ongoing use, such as reagents and assay kits. Additionally, Alamar offers services, likely including installation, training, maintenance, and support. The company's NULISA technology is central to its offerings, enabling detection and quantification of protein biomarkers. Revenue comes from global research institutions, biopharmaceutical companies, contract research organizations, and service labs.